# Carter BloodCare - Rosedale – FDA Inspection, Jan 16, 2019

Source: https://www.keypedia.com/records/fda_inspections/carter-bloodcare-rosedale/aa052737-64fd-4b38-bb15-1adc6592e280
Source feed: FDA_Inspections

> FDA inspection 1077022 of Carter BloodCare - Rosedale, January 16, 2019. Classification: No Action Indicated (NAI). 5 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1077022
- Company Name: Carter BloodCare - Rosedale
- Inspection Date: 2019-01-16
- Classification: No Action Indicated (NAI)
- Classification Code: NAI
- Project Area: Blood and Blood Products
- Product Type: Biologics
- Center: Biologics
- Office Name: Center for Biologics Evaluation and Research
- Citation Count: 0

## Related Documents

- FDA Inspection 1243500 - 2024-06-27
- FDA Inspection 1006650 - 2017-02-08
- FDA Inspection 917722 - 2015-02-05
- FDA Inspection 845620 - 2013-08-23
- [FDA Inspection 676470 - 2010-08-18](https://www.keypedia.com/records/fda_inspections/carter-bloodcare-rosedale/d650cf73-5dde-472e-9d94-83e19ec2b54a)

## Related Officers

- [Issuing Officer](https://www.keypedia.com/people/abby-l-mozeke/ce4ecbbc-0108-483e-aff3-d5320e50114f)

Company: https://www.keypedia.com/companies/carter-bloodcare-rosedale/2fd8b808-0c7c-48f2-a71d-5e492b705f60

Office: https://www.keypedia.com/offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d